anastrozole has been researched along with Invasiveness, Neoplasm in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer." | 9.27 | Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). ( Aono, T; Ito, T; Kagimura, T; Masuda, N; Matsunami, N; Miyoshi, Y; Nakayama, T; Noguchi, S; Sagara, Y; Taguchi, T; Takashima, T, 2018) |
| " We investigated antitumoral effects of the specific ETAR antagonist ZD4054 in breast cancer cells and xenografts, and assessed antitumoral efficacy of the combinations of ZD4054 with aromatase inhibitors and fulvestrant." | 7.76 | ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. ( Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P, 2010) |
| "We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)." | 7.73 | [Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005) |
| "This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer." | 5.27 | Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). ( Aono, T; Ito, T; Kagimura, T; Masuda, N; Matsunami, N; Miyoshi, Y; Nakayama, T; Noguchi, S; Sagara, Y; Taguchi, T; Takashima, T, 2018) |
| "This prospective substudy of the ATAC trial assessed BMD changes in postmenopausal women with invasive primary breast cancer receiving anastrozole (1 mg/d) or tamoxifen (20 mg/d) as adjuvant therapy for 5 years." | 5.13 | Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. ( Adams, JE; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Hannon, RA; Howell, A; Mackey, JR, 2008) |
| "A PubMed search (1966-July 2014) was conducted using the key terms breast cancer risk reduction, with anastrozole, exemestane, or letrozole, or aromatase inhibitors." | 4.90 | Aromatase inhibitors in breast cancer prevention. ( Olin, JL; St Pierre, M, 2014) |
| "The third generation aromatase inhibitors anastrozole, exemestane, and letrozole have been compared with tamoxifen and other endocrine therapies in several studies in early and advanced breast cancer." | 4.82 | Aromatase inhibitors in the treatment of early and advanced breast cancer. ( Ejlertsen, B; Joensuu, H; Lønning, PE; Rutqvist, LE, 2005) |
| " We investigated antitumoral effects of the specific ETAR antagonist ZD4054 in breast cancer cells and xenografts, and assessed antitumoral efficacy of the combinations of ZD4054 with aromatase inhibitors and fulvestrant." | 3.76 | ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. ( Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P, 2010) |
| "We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)." | 3.73 | [Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005) |
| "The condition is characterized by uterine leiomyomas associated with the development, typically years later, of slow-growing metastatic lesions." | 2.42 | Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. ( Christopoulos, S; Rivera, JA; Small, D; Trifiro, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsujio, G | 1 |
| Kashiwagi, S | 1 |
| Hatano, T | 1 |
| Asano, Y | 1 |
| Goto, W | 1 |
| Takada, K | 1 |
| Noda, S | 1 |
| Takashima, T | 2 |
| Onoda, N | 1 |
| Motomura, H | 1 |
| Hirakawa, K | 1 |
| Ohira, M | 1 |
| Nakayama, T | 1 |
| Sagara, Y | 1 |
| Matsunami, N | 1 |
| Masuda, N | 1 |
| Miyoshi, Y | 1 |
| Taguchi, T | 1 |
| Aono, T | 1 |
| Ito, T | 1 |
| Kagimura, T | 1 |
| Noguchi, S | 1 |
| Munoz, J | 1 |
| Kumar, VA | 1 |
| Hamilton, J | 1 |
| Pasche, LJ | 1 |
| Langford, LA | 1 |
| Taggart, MW | 1 |
| Kamiya-Matsuoka, C | 1 |
| Tummala, S | 1 |
| Moulder, S | 1 |
| Kurzrock, R | 1 |
| Olin, JL | 1 |
| St Pierre, M | 1 |
| Smollich, M | 1 |
| Götte, M | 1 |
| Fischgräbe, J | 1 |
| Macedo, LF | 1 |
| Brodie, A | 1 |
| Chen, S | 1 |
| Radke, I | 1 |
| Kiesel, L | 1 |
| Wülfing, P | 1 |
| Cruz Jurado, J | 1 |
| Richart Aznar, P | 1 |
| García Mata, J | 1 |
| Fernández Martínez, R | 1 |
| Peláez Fernández, I | 1 |
| Sampedro Gimeno, T | 1 |
| Galve Calvo, E | 1 |
| Murillo Jaso, L | 1 |
| Polo Marqués, E | 1 |
| García Palomo, A | 1 |
| Rivera, JA | 1 |
| Christopoulos, S | 1 |
| Small, D | 1 |
| Trifiro, M | 1 |
| Rao, GG | 1 |
| Miller, DS | 1 |
| Joensuu, H | 1 |
| Ejlertsen, B | 1 |
| Lønning, PE | 1 |
| Rutqvist, LE | 1 |
| Yuasa, H | 1 |
| Katsumine, Y | 1 |
| Uehara, S | 1 |
| Noda, N | 1 |
| Osawa, I | 1 |
| Eastell, R | 1 |
| Adams, JE | 1 |
| Coleman, RE | 1 |
| Howell, A | 1 |
| Hannon, RA | 1 |
| Cuzick, J | 1 |
| Mackey, JR | 1 |
| Beckmann, MW | 1 |
| Clack, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)[NCT02186015] | Phase 2 | 43 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessment of fatigue using the Piper Fatigue Scale at weeks 0 and 8. The Piper Fatigue Scale is the average of 22 numeric items, with higher scores indicating greater fatigue [range of scores: 0-10]. Change is calculated as the fatigue score at 8 weeks minus fatigue score at 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Cholecalciferol | -0.5 |
"Assessment of quality of life using the functional assessment of cancer therapy-breast symptoms at weeks 0 and 8. Scores range from 0-40 with higher scores indicating better quality of life.~Change was calculated as week 8 score minus week 0 score. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time." (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 0 |
Assessment of quality of life using the functional assessment of cancer therapy- endocrine symptoms at weeks 0 and 8. Scores range from 0-76 with higher scores indicating better quality of life. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 9 |
Assessment of mood using the Patient Health Questionnaire 8 (PHQ-8) at weeks 0 and 8. The PHQ-8 ranges from 0-24 with higher scores indicating more distress. Change was assessed as PHQ-8 score at 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | -1 |
Assessment of muscle function using a hand dynamometer at weeks 0 and 8. Change in dominant handgrip strength in kilograms was calculated as 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | kilograms (Median) |
|---|---|
| Cholecalciferol | -0.2 |
Change in laboratory serum value of 25(OH)D at 8 weeks post-supplementation for participants who received weekly supplementation of 50,000 IUs of vitamin D3. Change is expressed as laboratory serum value of 25(OH)D at 8 weeks minus baseline. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | ng/ml (Median) |
|---|---|
| Cholecalciferol | 32 |
Assessment of sleep using the Pittsburgh Sleep Quality Index (PSQI) at weeks 0 and 8. Scores range from 0-21 with higher scores indicating poorer sleep quality. Change was calculated as week 8 minus week 0 PSQI. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | -1 |
Assessment of pain using the Beck Pain Scale at weeks 0 and 8. This is a Likert scale item where a score of 0 corresponds to no pain and a score of 10 corresponds to worst pain. Change is calculated as the worst pain rating at 8 weeks minus the worst pain rating at 0 weeks.Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 0 |
5 reviews available for anastrozole and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female | 2014 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disea | 2011 |
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachial Plexus Neuropath | 2004 |
Clinical applications of hormonal therapy in ovarian cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Dose-Response Rela | 2005 |
Aromatase inhibitors in the treatment of early and advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adju | 2005 |
2 trials available for anastrozole and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2018 |
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Case-Co | 2008 |
4 other studies available for anastrozole and Invasiveness, Neoplasm
| Article | Year |
|---|---|
[A Case of Breast Cancer with Local Recurrence in the Reconstructed Breast Tissue].
Topics: Adult; Anastrozole; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Hormone Replacement Th | 2017 |
Posterior reversible encephalopathy syndrome: more than meets the eye.
Topics: Anastrozole; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Co | 2013 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast N | 2010 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2005 |